Earnings summaries and quarterly performance for Allarity Therapeutics.
Executive leadership at Allarity Therapeutics.
Board of directors at Allarity Therapeutics.
Research analysts covering Allarity Therapeutics.
Recent press releases and 8-K filings for ALLR.
Allarity Therapeutics Announces Opening of Phase 2 Clinical Trial Enrollment
ALLR
New Projects/Investments
- Allarity Therapeutics, Inc. announced on February 3, 2026, that enrollment has opened for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer (SCLC).
- This trial is being conducted in collaboration with the U.S. Department of Veterans Affairs (VA) and is fully funded by the VA, with enrollment open at 11 VA sites across the US.
- The study marks the first trial combining Allarity’s stenoparib with another anti-cancer agent, leveraging stenoparib's favorable safety profile for combination regimens.
3 days ago
Allarity Therapeutics Opens Enrollment for Phase 2 Trial of Stenoparib in Recurrent Small Cell Lung Cancer
ALLR
Product Launch
New Projects/Investments
- Allarity Therapeutics announced on February 3, 2026, that enrollment is now open for a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer (SCLC).
- This trial is the first to combine Allarity’s stenoparib with another anti-cancer agent and is fully funded by the U.S. Department of Veterans Affairs (VA), with enrollment available at 11 VA sites throughout the US.
- Stenoparib, a dual PARP and WNT pathway inhibitor, has demonstrated a favorable safety profile, making it a strong candidate for combination therapies in settings where tolerability has been a limiting factor.
4 days ago
Allarity Therapeutics Enters into $6 Million Equity Line of Credit
ALLR
- Allarity Therapeutics, Inc. (ALLR) entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC on January 28, 2026, establishing an equity line of credit.
- The agreement grants Allarity the right, but not the obligation, to sell up to $6,000,000 of newly issued common stock to Tumim Stone Capital LLC.
- Shares will be purchased at a discount to the volume-weighted average price (VWAP), specifically 95% of the lowest daily dollar VWAP for a one-day valuation period or 97% for a three-day valuation period.
- The agreement includes an Exchange Cap, limiting the issuance of shares to 19.99% of the common stock outstanding immediately prior to the agreement, unless stockholder approval is obtained or the average price of all applicable sales under the agreement equals or exceeds $3,214,588 (the Minimum Price).
- As consideration for the investor's commitment, Allarity Therapeutics paid a $45,000 commitment fee.
Jan 29, 2026, 12:49 PM
Allarity Therapeutics Reports New Clinical Data for Stenoparib in Advanced Ovarian Cancer
ALLR
New Projects/Investments
- Allarity Therapeutics, Inc. presented new and updated clinical data from its ongoing Phase 2 clinical trial for stenoparib/2X-121 in advanced ovarian cancer patients at the AACR 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025.
- The Kaplan-Meier analysis showed that the median Overall Survival (mOS) for patients receiving stenoparib/2X-121 twice daily has now exceeded 25 months.
- This mOS is approximately 10 months longer than the mOS reported for the most recent FDA approvals and advances in therapy for platinum-resistant ovarian cancer patients.
- Clinical benefit was evident in patients with BRCA wild-type as well as BRCA mutated genetics, with two patients continuing on therapy for over 24 months.
- An amended Phase 2 trial protocol, specifically for platinum-resistant or platinum-ineligible patients, has begun enrolling to accelerate stenoparib's clinical development towards FDA approval.
Sep 24, 2025, 11:58 AM
Allarity Therapeutics Enters into Securities Purchase Agreement for Private Placement
ALLR
- Allarity Therapeutics, Inc. entered into a Securities Purchase Agreement and a Registration Rights Agreement on September 22, 2025.
- The company agreed to sell 1,562,500 shares of common stock and/or pre-funded warrants in a private placement, with shares priced at $1.60 and pre-funded warrants at $1.5999.
- The initial closing, scheduled for September 23, 2025, is expected to generate approximately $2.5 million in gross proceeds for the company.
- The investor has the right for 90 calendar days following the initial closing to purchase additional shares and/or pre-funded warrants for aggregate gross proceeds of $7.5 million.
Sep 22, 2025, 9:30 PM
Allarity Therapeutics Receives FDA Fast Track Designation for Stenoparib
ALLR
New Projects/Investments
- Allarity Therapeutics, Inc. announced on August 26, 2025, that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to stenoparib, its investigational treatment for advanced ovarian cancer.
- This designation is intended to expedite the development and review of drugs for serious conditions with unmet medical needs, potentially allowing for accelerated approval and priority review.
- The company recently began patient enrollment for a new Phase 2 clinical trial evaluating stenoparib in advanced ovarian cancer, with the first patient enrolled in early June 2025.
- The trial is designed to accelerate the clinical development of stenoparib and its DRP® companion diagnostic.
Aug 27, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more